Pramanik S, Pal P, Ray S. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies. World J Methodol 2024; 14(2): 91319 [PMID: 38983664 DOI: 10.5662/wjm.v14.i2.91319]
Corresponding Author of This Article
Sayantan Ray, MBBS, MD, Assistant Professor, Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Sijua, Patrapada, Bhubaneswar 751019, Odisha, India. sayantan.ray30@gmail.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Methodol. Jun 20, 2024; 14(2): 91319 Published online Jun 20, 2024. doi: 10.5662/wjm.v14.i2.91319
Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies
Subhodip Pramanik, Partha Pal, Sayantan Ray
Subhodip Pramanik, Department of Endocrinology, Neotia Getwel Multispecialty Hospital, Siliguri 734010, West Bengal, India
Partha Pal, Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad 500082, India
Sayantan Ray, Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar 751019, Odisha, India
Author contributions: Pramanik S performed the literature search, wrote the first draft, and provided intellectual input; Pal P conceptualized the work, performed a literature search, and supervised the writing; Ray S supervised the literature search, and the writing, provided intellectual input and critically revised the manuscript.
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sayantan Ray, MBBS, MD, Assistant Professor, Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Sijua, Patrapada, Bhubaneswar 751019, Odisha, India. sayantan.ray30@gmail.com
Received: December 27, 2023 Peer-review started: December 27, 2023 First decision: January 5, 2024 Revised: January 20, 2024 Accepted: February 27, 2024 Article in press: February 27, 2024 Published online: June 20, 2024 Processing time: 170 Days and 5 Hours
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, affecting more than half of the people living with type 2 diabetes (T2D). The relationship between NAFLD and T2D is bidirectional and the presence of one perpetuates the other, which significantly increases the hepatic as well as extrahepatic complications. Until recently, there was no approved pharmacological treatment for NAFLD/ nonalcoholic steatohepatitits (NASH). However, there is evidence that drugs used for diabetes may have beneficial effects on NAFLD. Insulin sensitizers acting through peroxisome proliferator-activated receptor (PPAR) modulation act on multiple levels of NAFLD pathogenesis. Pioglitazone (PPARγ agonist) and saroglitazar (PPARα/γ agonist) are particularly beneficial and recommended by several authoritative bodies for treating NAFLD in T2D, although data on biopsy-proven NASH are lacking with the latter. Initial data on elafibanor (PPAR α/δ agonist) and Lanifibranor (pan PPAR agonist) are promising. On the other hand, incretin therapies based on glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) and dual- and triple-hormone receptor co-agonists reported impressive weight loss and may have anti-inflammatory and antifibrotic properties. GLP-1 RAs have shown beneficial effects on NAFLD/NASH and more studies on potential direct effects on liver function by dual- and triple-agonists are required. Furthermore, the long-term safety of these therapies in NAFLD needs to be established. Collaborative efforts among healthcare providers such as primary care doctors, hepatologists, and endocrinologists are warranted for selecting patients for the best possible management of NAFLD in T2D.
Core Tip: Co-existence of non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) synergistically act to increase the risk of adverse hepatic and extra hepatic outcomes. T2DM is an established risk factor for NAFLD progression to NASH, advanced fibrosis or cirrhosis. Timely intervention in these populations could have a significant effect on liver- related outcomes. Newer dual and pan-PPAR agonists show promising results in patients with NAFLD/NASH and T2DM. Incretin-based therapy for the treatment of NAFLD is currently being explored. With better understanding of the complex interaction between T2DM and NAFLD, PPAR agonists and incretin-based therapies are likely to provide more effective approach of NAFLD management in T2DM.
